Abstract
Cancer is one of the most prolific causes of death all around the world. Currently there is a huge focus around the globe on the identification of effective drugs against this disease. One important target is the development of new anti-angiogenic compounds. Fumagillin and other structurally related molecules are some of the most potent anti-angiogenic compounds reported to date with several currently being investigated in clinical studies.
Fumagillin has been used for more than 50 years against microsporidial parasites in animals, however, angiogenesis inhibition constitutes a new activity and an important research topic, this is the reason why nowadays some teams are working to achieve an effective way to obtain fumagillin analogues with more potent anti-angiogenic activity.
Here we present an overview on fumagillin and fumagillin analogues as leads products; we summarize the key structural features for antiangiogenic activity and discuss the total synthesis and synthesis of analogues and their biological activity.
Keywords: Angiogenesis, anti-angiogenic therapy, fumagillin, ovalicin, structure-activity relationship, TNP470, Nosema Apis, Nosema Ceranae, AGM-1470, Plasmodium falciparum, Pollini, Sorensen
Mini-Reviews in Organic Chemistry
Title:Fumagillin and Structurally Related Molecules as Source of New Drugs
Volume: 9 Issue: 2
Author(s): Diego Gamba-Sanchez
Affiliation:
Keywords: Angiogenesis, anti-angiogenic therapy, fumagillin, ovalicin, structure-activity relationship, TNP470, Nosema Apis, Nosema Ceranae, AGM-1470, Plasmodium falciparum, Pollini, Sorensen
Abstract: Cancer is one of the most prolific causes of death all around the world. Currently there is a huge focus around the globe on the identification of effective drugs against this disease. One important target is the development of new anti-angiogenic compounds. Fumagillin and other structurally related molecules are some of the most potent anti-angiogenic compounds reported to date with several currently being investigated in clinical studies.
Fumagillin has been used for more than 50 years against microsporidial parasites in animals, however, angiogenesis inhibition constitutes a new activity and an important research topic, this is the reason why nowadays some teams are working to achieve an effective way to obtain fumagillin analogues with more potent anti-angiogenic activity.
Here we present an overview on fumagillin and fumagillin analogues as leads products; we summarize the key structural features for antiangiogenic activity and discuss the total synthesis and synthesis of analogues and their biological activity.
Export Options
About this article
Cite this article as:
Gamba-Sanchez Diego, Fumagillin and Structurally Related Molecules as Source of New Drugs, Mini-Reviews in Organic Chemistry 2012; 9 (2) . https://dx.doi.org/10.2174/157019312800604724
DOI https://dx.doi.org/10.2174/157019312800604724 |
Print ISSN 1570-193X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6298 |
Call for Papers in Thematic Issues
Applications of Molecular Descriptors in Physicochemical Properties Research of Organic Compounds
Chemical graph theory is concerned with all aspects of the application of graph theory to various areas of chemistry, including organic, theoretical, mathematical, and computational chemistry, as well as in bioinformatics and computational biology. By the use of the term chemical it is emphasized that one is allowed in chemical ...read more
Navigating the 2D Universe in Organic Chemistry
This special issue explores the transformative impact of two-dimensional (2D) materials on the realm of organic chemistry, unraveling new possibilities for synthesis, functionalization, and applications of organic compounds. Focused on the unique chemistry within this novel dimension, the issue highlights breakthroughs in the field of 2D organic chemistry. Contributions are ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Third Generation Radiopharmaceuticals for Imaging and Targeted Therapy
Current Pharmaceutical Analysis In vitro Measurement and In vivo Prediction of Time-Dependent Inhibitory Effects of Three Tyrosine Kinase Inhibitors on CYP3A Activity
Current Drug Metabolism Mitochondrial Permeability Transition as Target of Anticancer Drugs
Current Pharmaceutical Design Histone Deacetylase Inhibitors in Psoriasis Therapy
Current Drug Targets - Inflammation & Allergy Neuropsychiatric Involvement in Systemic Lupus Erythematosus:Current Therapeutic Approach
Current Pharmaceutical Design Gemcitabine: A Critical Nucleoside for Cancer Therapy
Current Medicinal Chemistry Neurotransmitter Regulation of Adult Neurogenesis: Putative Therapeutic Targets
CNS & Neurological Disorders - Drug Targets Deubiquitinating Enzymes as Therapeutic Targets in Cancer
Current Pharmaceutical Design Regulation of MET Receptor Signaling by SOCS1 and its Implications for Hepatocellular Carcinoma
Current Pharmaceutical Design Innate Immunity and Intracellular Trafficking: Insights for Novel Anti- HIV-1 Therapeutics
Current Pharmacogenomics Epratuzumab and Blinatumomab as Therapeutic Antibodies for Treatment of Pediatric Acute Lymphoblastic Leukemia: Current Status and Future Perspectives
Current Medicinal Chemistry New Insights Into Biology of Chronic Myeloid Leukemia: Implications in Therapy
Current Cancer Drug Targets Hepatocellular Carcinoma: Important Biomarkers and their Significance in Molecular Diagnostics and Therapy
Current Medicinal Chemistry Anti-metastatic Treatment in Colorectal Cancer: Targeting Signaling Pathways
Current Pharmaceutical Design Disease Progression in HIV Late Presenters: the Role of HIV Clinical Indicator Diseases Prior to HIV Diagnosis
Current HIV Research The Role of cMet in Non-Small Cell Lung Cancer Resistant to EGFRInhibitors: Did We Really Find the Target?
Current Drug Targets Targeted Alpha Therapy with 213Bi
Current Radiopharmaceuticals Discovering Tumor Suppressor Genes Through Genome-Wide Copy Number Analysis
Current Genomics Preclinical Evaluation of New Anthracyclines
Current Medicinal Chemistry Drug Delivery Systems Based on Polymeric Micelles and Ultrasound: A Review
Current Pharmaceutical Design